NCT07190534View on ClinicalTrials.gov

The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

May 31, 2027

Conditions
Frontal Fibrosing AlopeciaCicatricial Alopecia
Interventions
DRUG

Hydroxychloroquine (HCQ)

400 mg orally once daily

DRUG

Methotrexate (MTX)

15 mg weekly, orally or subcutaneously (+ concomitant medication: Folic acid 10 mg once weekly, taken 24 hours after MTX)

Trial Locations (1)

3015GD

Erasmus MC University Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER